Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Keiji Sugiyama , Yukiya Narita , Seiichiro Mitani , Kazunori Honda , Toshiki Masuishi , Hiroya Taniguchi , Shigenori Kadowaki , Takashi Ura , Masashi Ando , Masahiro Tajika , Kei Muro
Background: Sarcopenia is a poor prognostic factor in several cancers. This study aimed to assess the predictive value of sarcopenia on survival outcomes among pts with mGC. Methods: We retrospectively analyzed 170 consecutive pts with mGC starting first-line chemotherapy at the single institution during January 2013–December 2014. Inclusion criteria were as follows: treatment with fluoropyrimidine plus platinum-based regimen, ECOG PS 0–2, and adequate organ function. Skeletal muscle index (SMI) was calculated from cross-sectional area of muscle at L3 using CT scan divided by the square of the height. Baseline sarcopenia (S) was defined as 53.4 cm2/m2 for men and 38.5 cm2/m2for women. Muscle loss after chemotherapy (L) was defined as 10% ≤ reduction in SMI. Univariate and multivariate analyses were conducted to identify whether S and L were independent prognostic factors of time to treatment failure (TTF) and overall survival (OS). Multivariate analysis included variables with p values ≤ 0.1 in univariate analyses. Results: Ninety-seven pts met the inclusion criteria; 83 (86%) were classified with S, and 39 (31%) with L. PS (0 vs. 1 and 2) and ALP (ULN> vs. ULN≤) were significantly associated with L. Overall response rate for S, non-S, L, and non-L was 60%, 63%, 63%, and 61%, respectively. S was not associated with TTF or OS. However, L was significantly associated with a shorter TTF (4.7 vs. 7.3 m, HR=1.82; 95% CI: 1.16-2.85, p=0.009) and tended toward worse OS (14.2 vs. 19.7 m, HR=1.31; 95% CI: 0.78-2.20, p=0.29). Variables with p values ≤ 0.1 in univariate analyses for TTF were L, LDH (ULN≤), ALB (ULN>), and histology (poorly differentiated). Histology was only variables with p values ≤ 0.1 for OS (p=0.002). As per multivariate analyses, only L was a significant prognostic factor of TTF. Conclusions: L is an independent negative prognostic factor of TTF in pts with mGC. Intervention for muscle loss can be a therapeutic approach for mGC.
Univariate | Multivariate | |||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Muscle loss | 1.82 (1.16-2.85) | 0.001 | 1.79 (1.14-2.81) | 0.01 |
LDH | 1.86 (1.13-3.09) | 0.01 | 1.56 (0.89-2.72) | 0.12 |
Alb | 1.47 (0.5-2.29) | 0.07 | 1.26 (0.78-2.72) | 0.34 |
Histology | 1.53 (0.96-2.44) | 0.07 | 2.65 (1.41-4.97) | 0.11 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2023 ASCO Annual Meeting
First Author: Yelena Y. Janjigian
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Yelena Y. Janjigian
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Ian Chau